Logo-jrip
Submitted: 23 Oct 2019
Accepted: 21 Apr 2020
ePublished: 29 May 2020
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Renal Inj Prev. 2021;10(3): e20.
doi: 10.34172/jrip.2021.20

Scopus ID: 85111309830
  Abstract View: 2124
  PDF Download: 1276

Original

Plasma N-terminal pro-brain natriuretic peptide level as a marker of adverse outcome in patients with co-existing diabetes, chronic kidney disease and heart failure

Amin Roshdy Soliman 1 ORCID logo, Rabab Mahmoud Ahmed 1* ORCID logo, Ahmad Yousry 2, Tarek Samy Abdelaziz 1* ORCID logo, Abdel Hakem Selem 2

1 Department of Internal Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt
2 Department of cardiology, Faculty of Medicine, Zagazig University, Zagazig, Egypt
*Corresponding Authors: *Corresponding author: Rabab Mahmoud Ahmed Mahmoud, Email: , Email: ruby_mahmoud_555@cu.edu.eg; Tarek Samy Abdelaziz, Email: , Email: Tarek. samy80@yahoo.com

Abstract

Introduction: N-terminal pro–B-type natriuretic peptide (NT-proBNP) is a novel marker of cardiac disease and heart failure; both are in patients with diabetes and chronic kidney disease.

Objectives: This study aimed to investigate the NT-proBNP and adverse outcome in patients with diabetes complicated by chronic kidney disease (CKD).

Patients and Methods: We measured the serum levels of NT-proBNP. The association of this novel marker with re-hospitalization and mortality rate were prospectively compared among the studied groups.

Results: Among 120 patients, baseline NT-proBNP at the time of admission was significantly elevated in patients with CKD (P= 0.001). Levels of NT-proBNP were significantly elevated in patients with diabetes and CKD than those with CKD alone (P= 0.04) at the end of follow-up. Higher proBNP levels significantly correlated with decreased glomerular filtration rate (GFR) and higher serum creatinine levels (P= 0.03, P< 0.001, respectively). In addition, increased mortality was noticed in those patients.

Conclusion: NT-proBNP levels have prognostic implication in the setting of CKD, diabetes mellitus and heart failure. Adverse outcomes are; a higher rate of need for dialysis, re-hospitalization and increased mortality which are correlated with levels of NT-proBNP.



Implication for health policy/practice/research/medical education:

Measuring N-terminal pro–B-type natriuretic peptide (NT-proBNP) level in patients with coexisting chronic kidney disease, diabetes and heart failure may predict the risk of adverse outcomes consisting, the need for dialysis, re-hospitalization and mortality.

Please cite this paper as: Soliman AR, Ahmed RM, Yousry A, Abdelaziz TS, Selem AH. Plasma N-terminal pro-brain natriuretic peptide level as a marker of adverse outcome in patients with co-existing diabetes, chronic kidney disease and heart failure. J Renal Inj Prev. 2021; 10(3): e20. doi: 10.34172/jrip.2021.20.


First Name
Last Name
Email Address
Comments
Security code


Abstract View: 2125

Your browser does not support the canvas element.


PDF Download: 1276

Your browser does not support the canvas element.